key: cord-0684737-api7ca1u authors: Núñez-Zapata, Susy Fanny; Benites-Peralta, Bruno; Mayta-Tristan, Percy; Rodríguez-Morales, Alfonso J. title: High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for heard immunity! date: 2021-07-11 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.07.022 sha: fcf729b755ce861246e1e02373a8938b74eb78b2 doc_id: 684737 cord_uid: api7ca1u Herd immunity is considered a relevant aspect of the COVID-19 epidemiology. In this regard, seroprevalence studies are essential to understand how far the countries and regions would be from that potential point. We analyzed seroprevalence data from nine studies in South America, a region that, as is known, has been strongly affected by COVID-19. Seroprevalence values ​​were high, with percentages that reach up to 70.0% (95%CI 67.0-73.4%) in Iquitos, Peru. A meta-analysis of such data allowed to obtain a pooled seroprevalence, estimated in 33.6% (95%CI 28.6-38.5). Despite this, the COVID-19 pandemic in South America continues to significantly affect countries such as Brazil, Colombia, and Peru. High seroprevalence for SARS-CoV-2 infection in South America, but still not enough for heard immunity! Susy Fanny Núñez-Zapata, 1,2, * Bruno Benites-Peralta, 1,3 Percy Mayta-Tristan, 1 Alfonso J. Recently, there has been an intense discussion about the importance of reaching herd immunity globally to achieve population protection status against SARS-CoV-2/COVID-19. For that reason, vaccination coverage and seroprevalence studies are increasing in the world. Nevertheless, unfortunately, some of them have shown an increase in the seroprevalence of different populations. For example, a recent study in Jordan (Sughayer et al., 2021) stated the importance of seroprevalence studies for SARS-CoV-2 infection among healthy blood donors. In this sense, we would like to complement by discussing some seroprevalence data in South America, a region that, as is known, has also been strongly affected by the coronavirus disease 2019 (COVID-19). Since its notification, COVID-19 has caused millions of people to be infected and thousands of deaths to occur worldwide. Therefore, to better manage the disease, health authorities need to know the prevalence. Although the RT-qPCR is the gold standard for its diagnosis, serological methods have the advantage of detecting the actual extent of the disease due to the permanence of anti-IgM and IgG immunoglobulins and because they also allow asymptomatic and subclinical infections to be captured (Xu et al., 2020) . Seroprevalence has already been determined in many countries (Rostami et al., 2021) , but in South America, there have only been a few initiatives carried out at the population level, including Argentina, Brazil (Hallal et al., 2020 , Colombia (Mattar et al., 2020) and Peru (Álvarez-Antonio et al., 2021 , Diaz-Velez et al., 2021 , Reyes-Vega et al., 2021 . Then our objective was to select relevant studies and assess the pooled seroprevalence of the region. We identified and selected studies about seroprevalence from Scielo, medRxiv/bioRxiv and PubMed from South America. The studies found include populations from regions (more than from institutions) with more than 500 inhabitants, carried out between April and September 2020. We included information about the location, setting, period of study, used serological method (ELISA or LFIA, chemioluminiscense, rapid tests), size of the study, and the value of the seroprevalence found, with their 95% confidence intervals (95%CI). Using the open software OpenMetaAnalyst®, we ran a random-effects model meta-analysis to estimate a pooled seroprevalence. We included nine studies from four countries: Argentina, Brazil, Colombia and Peru, ranging from 716 individuals (Peru) up to 31,165 (Brazil). Some countries, such as Iquitos (Peru) and Monteria (Colombia) had the highest peak of infection worldwide in July 2020. In Table 1 (Table 1 ). The meta-analysis of such data allowed to obtain a pooled seroprevalence, estimated in 33.6% (95%CI 28.6-38.5) ( Table 1) . Without a doubt, the seroprevalences of the South American populations during the first wave were higher than those reported by European cities where the highest seroprevalence was in the northern zone with 5.27% (95%CI 3.97-6.57%), even higher than that reported initially by the Asian country of Iran with 22.16% (95%CI 18.7-26.0%) (Rostami et al., 2021) . It is worth mentioning that the highest values, such as Peru, Colombia, Argentina and Brazil, came from low-income populations. The relationship with poverty has already been demonstrated in different studies. Beyond this, recent publications suggest that the herd immunity may not necessarily be enough to suppress the COVID-19 pandemic (Tkachenko et al., 2021) . The idea of herd immunity via natural infection rather than vaccination is a bit controversial, as it is not clear how long will the antibodies last, and whether re-infection or re-activation of the virus can occur after the antibodies starts weaning from the body (Sharma et al., 2021) . Antibody titer can wane within weeks after infection and the magnitude of the antibody neutralization in asymptomatics decreases faster than in symptomatics (Blasi et al., 2021 , Seow et al., 2020 . The data in all the studied regions were taken during the months where the highest infection peaks were reported. Therefore, it was expected that herd immunity would have been achieved as expected for Maranhao (Brazil) during that time. However, they could have been overestimated as expected; which apparently happened in Manaus and Iquitos (Sabino et al., 2021) , since until that moment it was unknown that new variants could appear that would later refute this claim. Also, although many inhabitants had already been infected, , a second wave appeared and even reinfections (1-2%) were reported, although are still under study. Even more, there is not a clear definition of the proportion of population vaccinated and infected in a given time, which is necessary to reach the "heard immunity". Some publications have indicated this may be as low as 10-25% (Kaushal et al., 2020) , while others as high as 60-70% (Gomes et al., 2020 . But again, beyond that, given the high levels found of seroprevalence, no further cases should be in those areas, but still COVID-19 transmission and cases occur. A limitation of these analyses is that we used retrospective data, ranging from May to September 2020. This is an important limitation as the seroprevalence almost a year later when vaccination has already begun in all the countries studied has probably had an impact in the current situation. Another limitation is that we used data bases that included some studies not peer reviewed (preprints). Then, with new studies, further analyses are expected after vaccination plans in the region, that still is slow, as in most countries, less than 15% of people have been fully vaccinated. Studies in the same areas after vaccination would be useful for comparison purposes. Additionally, although we did not analyze the mortality rates and their potential relationship with seroprevalence in the different countries analyzed during the same period, is known that herd immunity can only be achieved with vaccination, as the natural course of infection would yield an enormous fatality rate, and indeed in South America, this has been the case with a significant mortality. On the other hand, it is also postulated that the immunity developed would not last long, probably more than a year. The application of vaccines could be an alternative to achieve herd immunity. However, continuous modifications will have to be developed against the new SARS-CoV-2 variants, and the vaccination process accelerated before the cases increase again. Knowing the prevalence of COVID-19 in South America will still take time with the transmission of the Brazilian variant (Gamma, P.1) that is currently the most contagious lineage in this region and prevents achieving herd immunity; in the meantime, we can only take the measures to continue with the use of masks, hand washing and keeping distance in order to stop the transmission of the SARS-CoV-2 virus, and certainly increase vaccination. Variants are a growing concern for the potential compromise and reduction of efficacy of available vaccines (Focosi et al., 2021) . All authors declare no conflict of interest. Funding Source. Universidad Cientifica del Sur covered the APCs for this publication. Ethical Approval. Not required. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity SARS-CoV-2 seroprevalence study in SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys Estimating the herd immunity threshold by accounting for the hidden asymptomatics using a COVID-19 specific model Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans Combating COVID-19 pandemic in India: Demystifying the concept of herd immunity Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhao Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão Population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil Dramatic Rise of Seroprevalence Rates of SARS-CoV-2 Antibodies among Healthy Blood Donors: The evolution of a Pandemic Time-dependent heterogeneity leads to transient suppression of the COVID-19 epidemic, not herd immunity seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China